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Abstract
Eumycetoma is a chronic progressive disabling and destructive inflammatory disease which is commonly caused by the
fungus Madurella mycetomatis. It is characterized by the formation of multiple discharging sinuses. It is usually treated by
antifungal agents but it is assumed that the therapeutic efficiency of these agents is reduced by the co-existence of
Staphylococcus aureus co-infection developing in these sinuses. This prospective study was conducted to investigate the
safety, efficacy and clinical outcome of combined antibiotic and antifungal therapy in eumycetoma patients with
superimposed Staphylococcus aureus infection. The study enrolled 337 patients with confirmed M. mycetomatis
eumycetoma and S. aureus co-infection. Patients were allocated into three groups; 142 patients received amoxicillin-
clavulanic acid and ketoconazole, 93 patients received ciprofloxacin and ketoconazole and 102 patients received
ketoconazole only. The study showed that, patients who received amoxicillin-clavulanic acid and ketoconazole treatment
had an overall better clinical outcome compared to those who had combined ciprofloxacin and ketoconazole or to those
who received ketoconazole only. In this study, 60.6% of the combined amoxicillin-clavulanic acid/ketoconazole group
showed complete or partial clinical response to treatment compared to 30.1% in the ciprofloxacin/ketoconazole group and
36.3% in the ketoconazole only group. The study also showed that 64.5% of the patients in the ciprofloxacin/ketoconazole
group and 59.8% in the ketoconazole only group had progressive disease and poor outcome. This study showed that the
combination of amoxicillin-clavulanic acid and ketoconazole treatment is safe and offers good clinical outcome and it is
therefore recommended to treat eumycetoma patients with Staphylococcus aureus co-infection.
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Introduction
Mycetoma is a chronic granulomatous subcutaneous infec-
tion which is endemic in the tropical and subtropical regions of
Central and South-America, Asia and Africa. It is caused by
either bacteria (actinomycetoma) or fungi (eumycetoma).
Eumycetoma is highly endemic in Sudan and commonly
caused by the fungus Madurella mycetomatis [1,2,3,4]. Clinically,
mycetoma presents as a slowly progressive painless subcuta-
neous swelling commonly at the site of previous trauma.
Multiple secondary nodules evolve within the swelling,
suppurate and drain serous, sero-sanguinous or purulent
discharge [1–3]. The discharge is initially sterile, but later
on, may become exposed to secondary bacterial infections due
to poor hygiene [5]. Routine monitoring follow-up visits of
these patients at the Mycetoma Research Centre (MRC) of the
University of Khartoum, Sudan documented recurrent bacte-
rial co-infections with S. aureus infection [3,5].
Eumycetoma continues to pose management challenges.
The current management approach consists of a prolonged
course of drugs combined with surgery. Unfortunately, the
cure rate is rather low with a high recurrence rate [6-8].
Therefore there is a desperate need to make available novel
antifungal agents and to develop new approaches in the
endemic areas.
Several studies have confirmed that, the majority of the S.
aureus infection is of endogenous origin and nasal carriage of S.
aureus is the risk factor for developing a co-infection in many
skin and soft tissue infections [9–18]. In general, local bacterial
co-infections may disturb the local tissue environment reduc-
ing the antifungal drug efficacy, producing local metabolites
which are likely to induce changes that affect the healing
process and increase drug resistance [19,20]. Therefore
controlling bacterial co-infection by the use of appropriate
antibiotics could normalize the tissue environment and
therefore augment the efficacy of antifungal agents in the
management of eumycetoma.
With this background, this prospective study was set out to
determine the safety and efficacy of the combination of
ketoconazole and amoxicillin-clavulanic acid or ciprofloxacin as
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a first line treatment for patients with eumycetoma caused by M.
mycetomatis and S. aureus co-infection.
Materials and Methods
Study Design
This prospective study was conducted at the Mycetoma Research
Centre, University of Khartoum in the period between January
2011 and June 2013. It included 337 consecutive patients with
confirmed Madurella mycetomatis eumycetoma; based on a confirmed
grains culture, fine needle aspiration for cytology and/or histopath-
ologic examination of surgical biopsies. All patients had a S. aureus
co-infection at the time of enrollment. None of the patients had
previous surgical or medical treatment for eumycetoma.
All patients were carefully interviewed. Demographic informa-
tion was gathered on gender, age, social habits, co-morbidities and
history of hospitalization in the past year. All patients underwent a
thorough general and local physical examination. This included
lesion size in cm from fixed points, the number of active sinuses,
skin attachment to deep structures and disability.
The study population was divided according to their lesions’ size
into three groups; massive lesion (.10 cm in diameter), moderate
lesion (5–10 cm in diameter) and small lesion (,5 cm in diameter).
All patients had full blood count examination, hepatic and renal
function tests, radiological examination of the affected site
(anterio-posterior and lateral views) and lesion ultrasound exam-
ination. Anterior nares and sinuses swab cultures for S. aureus were
obtained from all patients as previously described [13,14]. The
bacteria were cultured and identified to the species level by Gram’s
staining, colonial morphology, biochemical testing; catalase,
DNAse and Coagulase tests. A co-infection was defined as a deep
wound infection as documented clinically by treating clinician and
culture isolates.
According to the results obtained from the sinus swab culture,
antibiotics were given in prolonged courses, each course lasted 12
weeks. Several courses were administered. In this study, the two
common antibiotics that showed organism’s sensitivity were
amoxicillin-clavulanic acid and ciprofloxacin. Patients were
allocated according to their bacteriology culture results into two
groups; the amoxicillin-clavulanic acid and ketoconazole group
and the ciprofloxacin and ketoconazole group. Ketoconazole was
the eumycetoma drug of choice at the MRC during the study
duration.
One hundred forty two patients received one gram amoxicillin-
clavulanic acid orally twice daily combined with oral ketoconazole
400 mg twice daily and 93 patients received oral ciprofloxacin
500 mg twice daily combined with oral ketoconazole 400 mg
twice daily. Another 102 patients from the MRC records who only
received 400 mg ketoconazole orally twice daily were selected and
included as a control group.
All patients were followed up closely every four weeks for
clinical, hepatic and renal functions assessment. The medical
treatment duration ranged between 6 months and one year
depending on clinical response followed by wide surgical excision.
Cure and amputation were considered as study outcomes. Cure
was defined as complete mass disappearance, healed sinuses,
normal skin and absence of hyper-reflective echoes and cavities on
ultra-sound examination [21].
Ethical Clearance
Ethical clearance was obtained from Soba University Hospital
Ethical Committee. Patients gave written informed consent.
Statistical Analysis
One way ANOVA was used to compare the mean of age, duration
and occupation for the three study groups. The clinical response to
the combinations of ketoconazole and the antibiotics was assessed
with the Fisher exact test. The significance of differences in patients
and control were calculated and p-value of ,0.05 considered
statistically significant. All statistical analyses were performed using
SPSS for Windows v11.0 statistical analysis software.
Results
Study Population
To test the hypothesis that eradicating secondary bacterial
infections would have a positive effect on the outcome of
eumycetoma treatment, 337 patients with confirmed M. mycetomatis
and S. aureus co-infection were enrolled in this study (Table 1).
All S. aureus strains were assessed for their susceptibility to a large
panel of antimicrobial agents. All strains were susceptible to
amoxicillin-Clavulanic acid and/or ciprofloxacin.
Adding Amoxicillin-Clavulanic Acid but Not Ciprofloxacin
to Ketoconazole Treatment Improves the Therapeutic
Outcome of Ketoconazole Treated Mycetoma Patients
with S. aureus Co-infection
The treatment duration in the amoxicillin-clavulanic acid group
ranged between 3 and 12 months (mean 9.6 months) and the
bacterial co-infection was eradicated in 97.2% of the patients. In
the ciprofloxacin group, the treatment duration ranged between 3
and 12 months (mean 10 months) and in this group, none of the
bacterial co-infection was eradicated.
Patients who had received a combination of amoxicillin-
clavulanic acid and ketoconazole had an overall better clinical
outcome than those received a combination of ciprofloxacin and
ketoconazole or ketoconazole alone.
In the amoxicillin-clavulanic acid group, 39 patients (27.5%),
showed complete and 47 patients (33.1%) had partial clinical
response to treatment compared to 13 patients (14%) complete
and 15 patients (16.1%) had partial response in the ciprofloxacin
Author Summary
Mycetoma, a unique neglected tropical disease, is char-
acterised by massive deformity and disability presenting
with painless subcutaneous mass, multiple sinuses that
produce sero-purulent discharge. Secondary bacterial
infection is common in mycetoma and it is assumed that,
this bacterial co-infection reduces the effectiveness of the
antifungal treatment and is responsible for the poor
treatment outcome. To investigate this hypothesis, this
study examined the combination of Ketoconazole and
antibiotics in two groups of patients with eumycetoma
and Staphylococcus aureus (S. aureus) co-infection. The first
group received ketoconazole and amoxicillin-clavulanic
and the second group received ciprofloxacin and ketoco-
nazole. The study also included a historical group of
patients who had only ketoconazole as a control group.
Patients who had amoxicillin-clavulanic acid and ketoco-
nazole had an overall better clinical outcome and superior
infection eradication compared to the two other groups. It
can be concluded that the combination of amoxicillin-
clavulanic acid and ketoconazole is safe treatment and
offers better clinical outcome in eumycetoma patients
with S. aureus co-infection.
Staphylococcus aureus Co-infection in Mycetoma
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group. In the ketoconazole group 22 patients (21%) had complete
response and 15 patients (14.7%) had partial response. Table 2,3.
The study also showed that 60 patients (64.5%) of the ciprofloxacin
group and 61 patients (59.8%) of the ketoconazole monotherapy
group had progressive disease and poor outcome, (Table 3).
Based on these results, it can be concluded that, the
combination of amoxicillin-Clavulanic acid and ketoconazole has
superior outcome in the treatment of eumycetoma patients with S.
aureus co-infection. This also suggests that treating co-infection
influences the outcome of the eumycetoma treatment with
ketoconazole.
Adding Amoxicillin-Clavulanic Acid but Not Ciprofloxacin
to Ketoconazole Treatment Improves the Skin
Abnormalities, Pain and Mobility of Eumycetoma Patients
with S. aureus Co-infection
In addition, to influencing the outcome of the ketoconazole
therapy, we investigated if treating the co-infection also play a role
in improving the skin abnormalities, the pain and even the
disability observed in the eumycetoma patients.
At the end of the study, 34.5% of the amoxicillin-clavulanic acid
patients group had skin appearance improvement in contra-
distinction to patients of the other two groups. (Fisher exact,
p= 0.000).
Although mycetoma is generally regarded as painless, pain can
be induced by secondary bacterial infections. In the amoxicillin-
clavulanic acid treated group significantly fewer patients (18
patients; 12.7%) suffered from pain in the lesion compared to the
ciprofloxacin treated group (79 patients; 85%), (Fisher exact,
p= 0.000).
At the end of the treatment period, the overall mobility of the
patients who received amoxicillin-clavulanic acid was significantly
better than those receiving ciprofloxacin. In the amoxicillin-
clavulanic acid group 123 out of 139 patients, had no disability,
versus 2 of the 93 in the ciprofloxacin treated group (Fisher exact,
p= 0.000). The degree of disability was more severe in the
ciprofloxacin treated group than in the amoxicillin-clavulanic acid
Table 1. Study population demographic features.
Characteristic
Amoxicillin-Clavulanic
Acid Group Ciprofloxacin Group
Ketoconazole Only
Group P-Value
Number 142 93 102)
Mean Age (Range) 29.99 (7–.76) 27.78 (12–60) 24.86(9–57 0.262
Gender (Male/Female) 112/30 79/14 67/35 0.002
Occupation Farmer 29(20.6) 24(25.8) 16(15.7) 0.058
Workers 44(31.2) 26(28) 17(16.7)
Student 41(29.1) 24(25.8) 34(33.3)
Housewife 17(12.1) 14(15.1) 23(22.5)
Jobless 8(5.7) 5(5.4) 10(9.8)
Other Job 3(2.11) 0(0.0) 2(2.0)
Mean Duration before
treatment6 SD (range)
7.6267.094 (1–38 Year) 6.6565.237 (1–23 Year) 6.3265.136 (1–23 Year) 1.000
The p value,0.05 was deemed statistically significant. Significant p values are highlighted in the boldfaced letters.
doi:10.1371/journal.pntd.0002959.t001
Table 2. The mycetoma treatment outcome in patients with a secondary S. aureus infection when treated with amoxicillin
clavulanic acid.
Clinical Evaluation Amoxicillin-Clavulanic Acid Group (N=142) Ketoconazole Only (N=102) P-Value*
Complete response 39 (27.5%) 22 (21.6%) 0.000
All sinuses closed and/or 36 03
Lesion disappeared completely- without relapse 03 19
Partial Response:. 47 (33.1%) 15 (14.7%) 0.547
.50% of sinuses are healed and/or 33 11
.50% decrease of the swelling size 14 04
Stable Disease 42 (29.6%) 4 (3.9%) 0.465
No change in sinuses and/or 23 03
No change in lesion size 19 01
Progressive Disease 14 (9.9%) 61 (59.8%) 0.130
Increased sinuses in number and/or 03 22
Increased lesion size 11 39
P-value as calculated by fisher exact test.
doi:10.1371/journal.pntd.0002959.t002
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treated group. Of the 91 patients with disabilities in the
ciprofloxacin-treated group, 77 had severe disability, while only
four out of the 16 in the amoxicillin-clavulanic acid treated group
were severely disabled (Fisher exact, p= 0.00). Four patients in
amoxicillin-clavulanic acid group and 11 patients in ciprofloxacin
group had amputation.
Combination of Amoxicillin-Clavulanic Acid or
Ciprofloxacin and Ketoconazole for the Treatment of
Eumycetoma Patients with S. aureus Co-infection Does
Not Affect the Hepatic Function
Ketoconazole administration in high doses is hepatotoxic and
therefore patients require close monitoring of their hepatic
functions during treatment [8]. Adding other medication to the
ketoconazole treatment regime could further influence the hepatic
functions. The total protein, albumin, globulin, bilirubin and the
liver enzymes; alkaline phosphates, serum glutamic oxaloacetic
transaminase (SGOT) and serum glutamate-pyruvate transami-
nase (SGPT) were measured at the start of the study, after one
month, 3 months, 6 months and 12 months in this study. The
addition of amoxicillin-clavulanic acid or ciprofloxacin to ketoco-
nazole did not result in hepatic toxicity. This suggests the safety of
this combination.
Discussion
Previous studies and clinical observations documented that,
bacterial co-infection is common in eumycetoma patients and S.
aureus is the most commonly isolated bacterial species [5]. The
bacterial infection may disturb the local environment, reduce drug
efficacy, and could produce local metabolites that may induce
changes affecting the healing process and increase drug resistance
[19,20]. Hence, it can be hypothesized that secondary bacterial
infections can influence the therapeutic outcome of the antifungal
treatment for eumycetoma patients.
In this study, S. aureus strains were tested for their susceptibility
to a large group of antibiotics and amoxicillin-clavulanic acid and
ciprofloxacin appeared to be the most effective ones. It is
interesting to note that, amoxicillin-clavulanic acid eradicated
the infection in most of the patients whereas the bacterial co-
infection persisted in all patients in the ciprofloxacin group. The
explanation of this is unclear but cases of ciprofloxacin resistant
staphylococci were reported even during the drug investigational
stage, and since its introduction into routine clinical use, there has
been increasing reports of ciprofloxacin-resistant staphylococci
[22–27]. It appears that once resistance developed, person-to-
person transmission within an environment favorable to spread
resulted in widespread dissemination of resistant strains [24,27].
Amoxicillin-clavulanic acid treatment resulted in eradication of
S. aureus co-infection in the affected patients, it is therefore not
surprisingly, that clinical improvement in these patients manifested
by reduction of lesion size, number of active sinuses and less
disability compared to the ciprofloxacin and the ketoconazole
monotherapy groups.
In untreated mycetoma, particularly those with lesions contain-
ing multiple active sinuses, disease progression results in further
tissue damage and destruction. It is highly likely that the bacterial
co-infection has a major role to play in the disease progression
[28].
It can be extrapolated from this observation that, the improved
clinical outcome is due to co-infection eradication leading to less
disease progression in the amoxicillin-clavulanic acid group
compared to the other groups.
In mycetoma, the criteria of clinical improvement include
lesion’s size reduction, reduced active sinuses, normal skin and
reduced disability. All these were documented in amoxicillin-
clavulanic acid group which is possibly due to eradiation of the co-
infection. It is interesting to note that the clinical improvement was
observed within the first three months of amoxicillin-clavulanic
acid treatment. This was not observed in the ciprofloxacin group
and it is likely to be due to the persistence of the secondary
bacterial infection and its local effects on the lesions.
The results obtained in this study are encouraging as
eradication of the co-infection was associated with better clinical
outcome. However ketoconazole the gold standard treatment for
mycetoma has a narrow safety margins. Van de Sande and
associates [29], Van Belkum and colleagues [30], Kloezen and
associates [31] showed in in vitro susceptibility testing, encouraging
results with the new generation of the azole group. [32–35].
Further studies combining amoxicillin-clavulanic acid with
voriconazole or posaconazole are recommended. Both voricona-
zole and posaconazole have a better safety-profile than the
Table 3. The mycetoma treatment outcome in patients with a secondary S. aureus infection when treated with ciprofloxacin.
Clinical Evaluation Ciprofloxacin Group (N=93) Ketoconazole Only (N=102) P-Value
Complete response 13 (14.0%) 22(21.%) 0.474
All sinuses closed and/or 03 03
Lesion disappeared completely- without relapse 10 19
Partial Response: 15 (16.1%) 15 (14.7%) 1.000
.50% of sinuses are healed and/or 11 11
.50% decrease of the swelling size. 04 04
Stable Disease 5 (5.3%) 4 (3.9%) 0.624
No change in sinuses and/or 01 03
No change in lesion size 04 01
Progressive Disease 60 (64.5%) 61 (59.8%) 0.704
Increased sinuses in number and/or 21 22
Increased lesion size 39 39
P-value as calculated by fisher exact test.
doi:10.1371/journal.pntd.0002959.t003
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currently used ketoconazole [32-35] and therefore avoiding liver
toxicity and hepatitis [36].
In conclusion, amoxicillin-clavulanic acid proved to be highly
effective in eradication of S. aureus co-infection in patients with
eumycetoma due to M. mycetomatis and was associated with good
clinical outcome and safety profile with no reported hepatic
toxicity. Combination of amoxicillin-clavulanic acid and new less
toxic azole drugs is recommended to avoid the toxic effect of
ketoconazole which was recently banned by the Food and Drugs
Administration (USA) (http://www.fda.gov/drugs/drugsafety/
ucm362415.htm).
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